兰索拉唑
埃索美拉唑
雷贝拉唑
奥美拉唑
泮托拉唑
医学
质子抑制剂泵
药效学
幽门螺杆菌
食管炎
药品
胃肠病学
反流性食管炎
内科学
药理学
药代动力学
胃酸
格尔德
疾病
胃
回流
出处
期刊:Gastroenterology Nursing
[Ovid Technologies (Wolters Kluwer)]
日期:2003-09-01
卷期号:26 (5): 182-190
被引量:47
标识
DOI:10.1097/00001610-200309000-00003
摘要
Proton pump inhibitors are the standard of treatment for acid-related disorders. These disorders include gastroesophageal reflux disease and its complications (i.e., erosive esophagitis and Barrett’s esophagus), peptic ulcer disease, Zollinger-Ellison syndrome, and idiopathic hypersecretion. Proton pump inhibitors are also successfully used for the treatment of Helicobacter pylori infection and upper gastrointestinal bleeding. There are currently five proton pump inhibitors approved by the Food and Drug Administration and available in the United States. These are omeprazole (Prilosec), lansoprazole (Prevacid), rabeprazole (Aciphex), pantoprazole (Protonix), and esomeprazole (Nexium). This review discusses the history of proton pump inhibitors and compares and evaluates the pharmacology including mechanism of action, pharmacokinetics, pharmacodynamics, administration, dosage, and drug interactions. Information regarding therapeutic indications, clinical efficacy, short- and long-term side effects, and cost is also presented. A case presentation offers an analysis of the use of proton pump inhibitors in individualized patient care.
科研通智能强力驱动
Strongly Powered by AbleSci AI